the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
Published 22 hours ago • 45 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
0:50
is the cr of mm patients a good objective for treatment?
-
1:08
promising new therapies for mm treatment
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
0:42
factors to consider when selecting patients with multiple myeloma for treatment with bispecifics
-
8:13
treatment strategies for high-risk mm
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
2:14
a new classification for identifying high-risk myeloma based on cytogenetic abnormalities
-
9:25
mgus diagnosis: a step-by-step approach
-
0:59
investigating jak2v617f as a therapeutic target in mpns
-
6:23
radiotherapy treatment
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
2:42
optimizing maintenance therapy in multiple myeloma: an analysis from the preamble registry
-
2:48
the promise of pyruvate kinase activators, such as mitapivat, for treating scd and thalassemia
-
1:23
tourmaline-mm1 updates: importance and challenges of adjusting for subsequent therapies
-
1:17
frailty-adapted therapy in myeloma: session takeaways
-
2:45
continuity of care for patients with hematological predispositions to aml
-
1:42
the future of cll treatment: aiming for long-lasting remission
-
1:07
how covid-19 has impacted clinical practice and treatment approaches in multiple myeloma
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:06
evolving strategies for second- and third-line treatments in multiple myeloma